The active ingredient in Zunveyl is benzgalantamine, a prodrug of galantamine, a competitive and reversible inhibitor of actylcholinesterase.

"The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease," said Lauren D’Angelo, COO and chief ...

Alpha Cognition (ACOG) announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This ...

The company’s nationwide salesforce is fully deployed and actively engaging with healthcare providers to ensure that ZUNVEYL reaches the patients who need it most. The commercial strategy is ...

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Since these tablets are used for the company’s upcoming launch of ZUNVEYL, a treatment for Alzheimer’s disease, this new patent will significantly improve Alpha Cognition’s position in the market.

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL ...

Analyst projects Zunveyl could reach $540M in peak U.S. sales by the late 2030s. Join Nic Chahine live on Wednesday, March 19, at 6 PM ET for a step-by-step breakdown of how to to capitalize on ...

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new ...